A Randomized, Double-Blind, Placebo-Controlled Study to Determine Safety and Tolerability of LX6171 Oral Suspension Dosed for 28 Days in Subjects Exhibiting Age Associated Memory Impairment (AAMI) with a Lead-in, Open-Label, Single-Dose Relative Bioavailability Study of LX6171 Oral Suspension in Healthy Elderly Subjects.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Determine Safety and Tolerability of LX6171 Oral Suspension Dosed for 28 Days in Subjects Exhibiting Age Associated Memory Impairment (AAMI) with a Lead-in, Open-Label, Single-Dose Relative Bioavailability Study of LX6171 Oral Suspension in Healthy Elderly Subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Apr 2012

At a glance

  • Drugs LX 6171 (Primary)
  • Indications Memory disorders
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Lexicon Pharmaceuticals
  • Most Recent Events

    • 02 Apr 2012 Inclusion and exclusion criteria amended as reported by European Clinical Trials Database record.
    • 24 Mar 2012 Primary endpoints identified as reported by European Clinical Trials Database record.
    • 24 Mar 2012 Planned number of patients changed from 120 to 136 as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top